SecBot SecBot
SECBOTREPLAY Home › Report › TOVX

TOVX · Theriva Biologics reported financial results for 2025 and provided…

Theriva Biologics, Inc. · 8-K filed Mar 12, 2026 at 08:11 ET

At the news

MIXEDIMPACT 6/10

8-K filed Mar 12, 2026 at 08:11 ET

Theriva Biologics reported financial results for 2025 and provided corporate updates, including licensing SYN-020 to Rasayana Therapeutics for up to $38 million in potential milestones, advancing VCN-01 toward pivotal trials in pancreatic cancer and retinoblastoma, and maintaining a cash runway into Q1 2027. The company incurred a net loss of $23.7 million in 2025, driven by a $9 million contingent consideration adjustment.

  • Licensed SYN-020 to Rasayana Therapeutics for up to $38 million in potential milestones plus royalties
  • Received $300,000 upfront payment from Rasayana with potential for $16M in development milestones and $22M in sales milestones
  • Cash and cash equivalents were $13.1 million as of December 31, 2025, with $15.2 million as of February 26, 2026
  • Net loss of $23.7 million for 2025, compared to $25.7 million in 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access